Recurrent venous thromboembolism (VTE, or deep vein thrombosis and pulmonary
embolism) is associated with mortality and long-term morbidity. The circumstances in which …

Venous thromboembolism (VTE) that includes deep vein thrombosis and/or pulmonary
embolism is a frequent, severe, and potentially lethal disease. After a first episode, VTE has …

Essentials• Reports on recurrence and mortality after a first venous thromboembolism (VTE)
vary considerably.• We describe rates of recurrence and mortality in patients with a first VTE …

In patients with venous thromboembolism (VTE), assessment of the risk of fatal recurrent
VTE and fatal bleeding during anticoagulation may help to guide intensity and duration of …

Essentials• Long‐term recurrence risk of venous thromboembolism (VTE) is uncertain.• We
performed a prospective cohort study of 839 patients with first unprovoked VTE.• VTE …

Background The duration of anticoagulation therapy after venous thromboembolism (VTE)
should be based on the balance between risks of recurrent VTE and bleeding. However …

Whether to continue oral anticoagulant therapy indefinitely after completing 3 to 6months of
oral anticoagulant therapy for “unprovoked” venous thromboembolism (VTE), is one of the …

Venous thromboembolism (VTE) is a disease, which often recurs. The recurrence risk is
highest in patients with unprovoked proximal deep-vein thrombosis (VT) or pulmonary …

Background: Case-fatality rates are important for assessing the risks and benefits of
anticoagulation in patients with venous thromboembolism (VTE). Purpose: To summarize …

To optimize patient outcomes with anticoagulation for venous thromboembolism (VTE), it is
essential to assess patients for their recurrence risk. In this article, I will review the impact of …